Sorrento Therapeutics (SRNE) Posts Q3 GAAP Loss of 27c/Share

Sorrento Therapeutics (NASDAQ: SRNE) reported Q3 EPS of ($0.27), which may not compare with the analyst estimate of ($0.32). Revenue for the quarter came in at $1.28 million versus the consensus estimate of $760 thousand.

For earnings history and earnings-related data on Sorrento Therapeutics (SRNE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)
• SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%